Appointment of Warren East to Advisory Board endorses market opportunity for human signs monitoring
Oxehealth, the spin-out from the University of Oxford’s Institute of Biomedical Engineering, today underlined its intention of delivering on the high growth potential of its non-contact vital signs technology with the appointment of a highly experienced technology innovator: Warren East.
Recently announced CBE recipient, Warren is former ARM CEO, board member of Rolls Royce, De La Rue, Dyson and BT, and winner of Computer Weekly’s UKtech 50 ‘The most influential people in UK IT’.
Warren joins the Oxehealth Advisory Board, bringing with him his knowledge of delivering successful long term innovation and growth strategies in fast moving and competitive technology markets.
As CEO of ARM Holdings, the world’s leading semiconductor intellectual property supplier, Warren was a key driver in the development of the technology that lies at the heart of many of today’s advanced digital electronic products. He will bring a breadth of insight and perception to advise on the routes to deliver Oxehealth’s innovative clinical technology, as well as bringing his understanding of the market to develop partnership opportunities.
This new appointment enhances the blend of academia and commercial leadership of Oxehealth. The company delivers patented software solutions that work in the real world and utilise innovative, clinically validated algorithms. Its patented Oxecam clinical technology, developed by world-leading scientist Professor Lionel Tarassenko and backed by IP Group plc., enables a digital camera, tablet or phone to monitor the vital signs of an individual, without the need for physical contact or expensive proprietary equipment.
Warren’s IT business background will be invaluable in Oxehealth’s bid to commercialise its proprietary algorithms by licensing software to established global providers of consumer and clinical health services and products. He joins the Advisory Board at a very exciting time in the product development, with practical clinical studies already completed in the Kidney Unit at Oxford University Hospitals NHS Trust and new studies starting shortly.
“I am delighted to have the opportunity to work with such an exciting start-up and believe my experience with ARM’s partnership and licensing business model combined with the world-class innovation from the University of Oxford’s Institute of Biomedical Engineering will help lead to a successful venture,” said Warren East.
Once credentials have been established in healthcare markets, leveraging clinical evidence and proof points, Oxehealth intends to offer its technology into markets including retail, security, automotive and beyond.
Notes to Editor:
Oxehealth Ltd is a software developer spun out from the University of Oxford’s Institute of Biomedical Engineering in 2012. Oxehealth is focused on providing advanced solutions which monitor vital signs. It does this through a range of software products with embedded intelligent algorithms which combine three key attributes: complex signal processing to allow accurate non-contact monitoring; machine learning, to provide personalised healthcare models; and clinical validation.
These solutions have the capability to transform the next generation of healthcare and patient monitoring. Its patented Oxecam clinical technology developed in the research labs of world-leading scientist Professor Lionel Tarassenko and backed by IP Group plc., enables a digital camera to monitor the vital signs (heart rate, respiratory rate and oxygen saturation) of individuals, without the need for expensive proprietary equipment. The vital sign measurements have been clinically validated in studies at the Oxford Kidney Unit.
Applications for the clinical technology include post-operative monitoring, COPD, assisted living, and providing lower cost smartphone or webcam diagnostics in inaccessible situations such as underdeveloped third world countries. There are also opportunities in other sectors such as automotive, where the continuous monitoring of vital signs could be life-saving.
For further information, contact Louise Fielding-Smith, Senior PR and social media account executive at firstname.lastname@example.org or on 01962 677 002, 07877 340671.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate